AdaptHealth Corp. Announces First Quarter 2025 Earnings Release Date and Conference Call
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- AdaptHealth Corp. (NASDAQ: AHCO) ('AdaptHealth' or the 'Company'), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, will release its first quarter 2025 financial results before the opening of the financial markets on Tuesday, May 6, 2025. Management will host a teleconference at 8:30 a.m. ET to discuss the results and business activities with analysts and investors.
Interested parties may participate in the call by dialing:
(800) 343-5172 (Domestic) or
(203) 518-9856 (International)
When prompted, reference Conference ID: AHCO1Q25
Webcast registration: Click Here
Following the live call, a replay will be available for six months on the Company's website, www.adapthealth.com under "Investor Relations."
About AdaptHealth Corp.
AdaptHealth is a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services. The Company operates under four reportable segments that align with its product categories: (i) Sleep Health, (ii) Respiratory Health, (iii) Diabetes Health, and (iv) Wellness at Home. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including CPAP and BiLevel services) to individuals for the treatment of obstructive sleep apnea. The Respiratory Health segment provides oxygen and home mechanical ventilation equipment and supplies and related chronic therapy services to individuals for the treatment of respiratory diseases, such as chronic obstructive pulmonary disease and chronic respiratory failure. The Diabetes Health segment provides medical devices, including continuous glucose monitors and insulin pumps, and related services to patients for the treatment of diabetes. The Wellness at Home segment provides home medical equipment and services to patients in their homes including those who have been discharged from acute care and other facilities. The segment tailors a service model to patients who are adjusting to new lifestyles or navigating complex disease states by providing essential medical supplies and durable medical equipment.
The Company is proud to partner with an extensive and highly diversified network of referral sources, including acute care hospitals, sleep labs, pulmonologists, skilled nursing facilities, and clinics. AdaptHealth services beneficiaries of Medicare, Medicaid, and commercial insurance payors, reaching approximately 4.2 million patients annually in all 50 states through its network of approximately 660 locations in 47 states.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Adobe Shares Slump as Q2 Beat Fails to Deliver a Catalyst
June 13 - Shares of Adobe (NASDAQ:ADBE) slipped about 4% in Friday's premarket trading after its fiscal second-quarter results topped forecasts but failed to sway investor sentiment. The company posted a modest beat on both revenue and earnings per share. It also raised its full-year revenue outlook, aided in part by favorable foreign exchange. Despite the gains, analysts noted the lack of a clear near-term growth catalyst. Evercore, which kept an Outperform rating and a $475 target, said the quarter offered no real fireworks for either bulls or bears. The firm said Adobe needs to reshape its broader investment case before attracting fresh interest. Morgan Stanley reiterated its Overweight rating with a $510 price target. Analysts said the print was largely in line, with improving AI adoption not yet showing a major impact on results. Jefferies maintained a Buy rating and a $590 target, pointing to steady progress in AI. The firm said Firefly and Acrobat AI saw growing traction, while AI-generated content rose 20% quarter over quarter. Still, analysts flagged that digital media recurring revenue guidance points to slower growth in the second half, which could keep shares range-bound for now. This article first appeared on GuruFocus.
Yahoo
8 minutes ago
- Yahoo
SSCP Lager BidCo AB (publ) successfully issues subsequent notes of SEK 200 million
SSCP Lager BidCo AB (publ) ('Logent' or the 'Company') has successfully issued subsequent senior secured floating rate notes in an amount of SEK 200,000,000 under the terms and conditions of the Company's outstanding notes loan 2023/2026 with ISIN SE0021021193 (the 'Subsequent Notes'). The order book was significantly oversubscribed, and the Subsequent Notes were issued to 102 per cent. of nominal amount. The Subsequent Notes carry a floating interest rate of 3m Stibor + 625 basis points and will mature in December 2026. Logent intends to apply for admission to trading of the Subsequent Notes on the corporate bond list of Nasdaq Stockholm. The net proceeds from the issuance of the Subsequent Notes will be applied towards consummation of the acquisition of the Finnish entity HUB logistics Finland Oy, financing transaction costs and general corporate purposes. Following the issuance of the Subsequent Notes, the aggregate outstanding nominal amount under the notes loan is SEK 1,050 million. The Company has mandated Nordea Bank Abp and Pareto Securities AS as Joint Bookrunners in connection with the issuance of the Subsequent Notes. Snellman Advokatbyrå AB has acted as legal advisor to the Company and Gernandt & Danielsson Advokatbyrå KB has acted as legal advisor to the Joint Bookrunners. For further information, please contact: Joel Engström, CEO, telephone number: +46 734 36 36 29, About Logent GroupLogent is an independent logistics partner, with a Nordic base present in Northern Europe and global networks. We have a wide range of services and create value for our customers through guaranteed cost and quality improvements. Our service offer include Logistics Services such as Warehouse design and operations, Transport Management and Customs, Port and Terminal operations, Staffing Services and Consulting Services. This means that Logent has grown to a turnover of about SEK 2.4 billion from the start in 2006 and employs approximately 2,800 people in Northern Europe. Attachment in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders
MISSISSAUGA, ON, June 13, 2025 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced that it held its annual and special meeting of shareholders earlier today and that all matters put forward before shareholders for consideration and approval as set out in the Company's management information circular dated May 2, 2025 were approved by the requisite majority of votes cast at the meeting. In particular, shareholders approved the election of all director nominees, the re-approval of RSM Canada LLP as auditor of the Company and the resolution approving the unallocated shares, rights and other entitlements under the Company's share purchase plan. A total of approximately 13 million shares, representing approximately 50.9% of the total shares outstanding were represented in person or by proxy at the meeting. The detailed results of the vote for the election of directors of Cipher is set out below: Nominee Votes For % Votes For Votes Withheld % Votes Withheld Craig Mull 11,476,390 96.15 % 459,043 3.85 % Harold Wolkin 11,475,560 96.15 % 459,873 3.85 % Douglas Deeth 11,864,293 99.40 % 71,140 0.60 % Hubert Walinski 11,806,918 98.92 % 128,515 1.08 % About Cipher Pharmaceuticals Inc. Cipher Pharmaceuticals (TSX:CPH) (OTCQX:CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America. For more information, visit SOURCE Cipher Pharmaceuticals Inc. View original content:
